CD19 and congenital rubella syndrome: Then, we evaluated the impact of ruxolitinib and DEX on cytokine production with an in vitro CRS model by co‐culturing 5 × 104 Nalm6 (CD19+) cells, 1 × 104 monocytes and 5 × 104 CD19 CAR T cells.28